Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Inhibikase Therapeutics (IKT) Long-Term Debt Issuances (2020)

Inhibikase Therapeutics (IKT) has disclosed Long-Term Debt Issuances for 1 consecutive years, with $27550.0 as the latest value for Q2 2020.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $27550.0 in Q2 2020 year-over-year; TTM through Dec 2021 was $27550.0, a 89.9% decrease, with the full-year FY2020 number at $272800.0, changed N/A from a year prior.
  • Long-Term Debt Issuances was $27550.0 for Q2 2020 at Inhibikase Therapeutics, down from $245250.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $245250.0 in Q1 2020 to a low of $27550.0 in Q2 2020.